AGIOS PHARMACEUTICALS, INC. Defined Contribution Plan, Employer Matching Contribution, Percent of Match
AGIOS PHARMACEUTICALS, INC. (AGIO) reported Defined Contribution Plan, Employer Matching Contribution, Percent of Match of 100.00% for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-12.
Financial Statements › Notes › Compensation Related Costs › Defined Contribution Plan
us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch · last filed 2026-02-12
- AGIOS PHARMACEUTICALS, INC. defined contribution plan, employer matching contribution, percent of match for fiscal 2025 was 100.00%, a 0.00% change from fiscal 2024.
- AGIOS PHARMACEUTICALS, INC. defined contribution plan, employer matching contribution, percent of match for fiscal 2024 was 100.00%, a 0.00% change from fiscal 2023.
- AGIOS PHARMACEUTICALS, INC. defined contribution plan, employer matching contribution, percent of match for fiscal 2023 was 100.00%, a 0.00% change from fiscal 2022.
- AGIOS PHARMACEUTICALS, INC. defined contribution plan, employer matching contribution, percent of match for fiscal 2022 was 100.00%, a 0.00% change from fiscal 2021.
| Period end | Defined Contribution Plan, Employer Matching Contribution, Percent of Match 12 month |
|---|---|
| 2025-12-31 | 100.00% 10-K · filed 2026-02-12 |
| 2024-12-31 | 100.00% 10-K · filed 2025-02-13 |
| 2023-12-31 | 100.00% 10-K · filed 2024-02-15 |
| 2022-12-31 | 100.00% 10-K · filed 2023-02-23 |
| 2021-12-31 | 100.00% 10-K · filed 2022-02-24 |
| 2020-12-31 | 100.00% 10-K · filed 2021-02-25 |
| 2019-12-31 | 100.00% 10-K · filed 2020-02-19 |
| 2018-12-31 | 100.00% 10-K · filed 2019-02-14 |
| 2017-12-31 | 50.00% 10-K · filed 2018-02-14 |
| 2015-12-31 | 50.00% 10-K · filed 2017-02-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| Zymeworks Inc. (ZYME) | United States | $1.902B | -12.44 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |